Fungemia Survey in Cancer Patients
- Determine the incidence of fungemia in relation to the number of admissions to the
hospital in patients with solid tumor or hematologic malignancy or in patients who have
undergone hematopoietic stem cell transplantation.
- Determine the fungal species distribution, prognostic factors for outcome, and crude
and attributable mortality in patients also diagnosed with fungemia.
OUTLINE: This is a multicenter, nonrandomized, prospective study.
- Group A (no documented fungemia at study entry): Data regarding the number of patients
with cancer or who have undergone hematopoietic stem cell transplantation, including
those who develop documented fungemia, who are admitted to the hospital is collected
for 2 years.
- Group B (documented fungemia at study entry): Fungal strains isolated from the initial
positive blood culture are collected and undergo examination, including confirmation of
species identification, susceptibility testing, and/or minimum inhibitory concentration
determination. Data, including antifungal treatment, clinical and microbiological
response to antifungal treatment (at 2, 4, and 12 weeks after diagnosis), and survival
status, is collected for each documented fungemia episode* for up to 12 weeks after
diagnosis of fungemia.
NOTE: *That occurs within a 2-year period.
PROJECTED ACCRUAL: A total of 300 patients will be accrued for this study.
Relative incidence of fungemia
German Hodgkin's Lymphoma Study Group
United States: Federal Government